MGTX vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

MGTX

57.7
AI Score
VS
MGTX Wins

DNA

53.0
AI Score

Investment Advisor Scores

MGTX

58score
Recommendation
HOLD

DNA

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MGTX DNA Winner
Revenue 11.98M 19.47M DNA
Net Income -104.24M -82.59M DNA
Net Margin -870.4% -424.1% DNA
Operating Income -93.31M -71.37M DNA
ROE -113.4% -18.6% DNA
ROA -39.0% -8.0% DNA
Total Assets 267.19M 1.03B DNA
Cash 63.37M 143.86M DNA
Current Ratio 1.63 5.15 DNA
Free Cash Flow -107.96M -48.62M DNA

Relative Price Performance (Last 90 Days)

MGTX 1M: -14.7% · 3M: +26.2% DNA 1M: -14.0% · 3M: -7.8%

Current Technical Phase

MGTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.3 · Price: $11.88

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 56.4 · Price: $8.94

Fundamentals Snapshot

Metric MGTX DNA
Market Cap
Forward P/E -9.7 -2.8
Trailing P/E
Revenue (TTM)
Revenue Growth -0.8% -0.5%
Gross Margin 1.0% 0.7%
Operating Margin -139.3% -3.7%
EPS -1.48 -5.38
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MGTX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.